Early bird registration is open and closes May 2025. Register now
Early bird registration is open and closes May 2025. Register now
Redefining the Autoimmune ILD Journey: From Early Risk Recognition to Long Term Care Objectives:Autoimmune diseases are a major cause of interstitial lung disease (ILD), with pulmonary fibrosis driving morbidity and mortality. This session will examine risk identification, key clinical and radiological signals of progression, and translation of guidelines into personalised care, concluding with emerging concepts and innovations shaping the future management of autoimmune ILD. Agenda – Saturday 31 October Chairperson: Prof Shin-Seok Lee, Republic of Korea 1250-1300 Opening and welcome
Title TBC Information coming soon Agenda – Saturday 31 October Chairperson: Prof Seung-Ki Kwok, Republic of Korea TBC Presentation title TBC Prof Kunihiro Yamaoka, Japan
Transforming the Trajectory: Early Inflammation Control as a Path to Lasting Change in Spondyloarthritis Agenda – Saturday 31 October Chairperson: Prof Kichul Shin, Republic of Korea TBC Presentation title TBC Prof Masato Okada, Japan TBC Presentation title TBC Prof Paul Bird, Australia
Objectives: Cytokine-targeted therapies continue to improve the treatment landscape of rheumatic and autoinflammatory diseases. This symposium will focus on the evolving role of IL-1 and IL-6 pathway targeting, highlighting recent clinical evidence and practical experience with olokizumab and goflikicept across adult and pediatric inflammatory disorders. Experts will discuss current challenges in disease management, emerging therapeutic approaches, and the future potential of targeted cytokine inhibition in improving long-term patient care. Agenda – Friday 30 October Chairperson: A/Prof Jose Paulo Lorenzo, Philippines
SpArkling Insights on SpA Synopsis:Join us for an engaging talk show dedicated to advancing the standard of care for patients with SpA. The speakers will tackle the challenges in diagnosis and long-term management, sharing insights from clinical trials and real-world experience. This is a unique opportunity for all rheumatologists passionate about SpA to gain practical knowledge and to help elevate care for patients. Don’t miss your chance to be part of this transformative discussion. Agenda – Thursday 29 October Workshop
Crossroads of Inflammation: What Advances in PsA/SpA Mean for Clinical Practice Synopsis: The APEX study evaluated guselkumab in adults with active, erosive psoriatic arthritis and demonstrated meaningful clinical and radiographic benefits through Week 48. Participants met predefined activity and erosive criteria and were randomized to two guselkumab dosing regimens or placebo with crossover at Week 24. By Week 48, both guselkumab schedules showed sustained improvements in ACR20 and ACR50 responses, along with continued suppression of radiographic progression, while patients switched
Title coming soon Objectives: Information coming soon.
Tacrolimus strategy for Autoimmune real-world in Rheumatic Disease Objectives: Information coming soon.
The significance of IL-6 signal blocking in autoimmune diseases including RA Objectives: At this sponsored symposium, lectures will be provided by Japanese and Korean opinion leaders on the importance of blocking IL-6 signaling in autoimmune diseases, particularly RA. Agenda – Friday 30 October Chairpersons: Prof Tsutomu Takeuchi, Japan and Prof Sang-heon Lee, Republic of Korea 1730-1755 Current Landscape and Clinical Experience of IL-6 Receptor Inhibition in Korean RA Patients Prof Chan-bum Choi, Republic of Korea 1755-1820 The Efficacy of IL-6
Have you submitted your abstract yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.